~~<i id='90252A2D6E'><strike id='90252A2D6E'><tt id='90252A2D6E'><pre id='90252A2D6E'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：leisure time 2025-09-28 12:46:40 Page View：8

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： These geoengineering technologies could help combat the climate crisis, scientists say
Next article： The cancer drug shortage isn’t new — and neither are the solutions

comprehensive

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

RafaelMarianoGrossi,DirectorGeneraloftheInternationalAtomicEnergyAgency,listenstoareporter'squestion

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

RafaelMarianoGrossi,DirectorGeneraloftheInternationalAtomicEnergyAgency,listenstoareporter'squestion